Solvay announced that it has completed the sale of its North American and European amphoteric surfactant business to OpenGate Capital, a private equity firm with headquarters in Los Angeles.

The sale includes the three main production sites supporting the amphoteric product lines located in University Park, Illinois (USA), Genthin (Germany), Halifax (United Kingdom), and a tolling arrangement in Turkey. The agreement also includes tolling and service agreements between Solvay and OpenGate to ensure a seamless transition and minimal customer disruption.

“OpenGate has proven to be a strong buyer for our North American and European amphoteric surfactant business,” commented Michael Radossich, President of Solvay’s Novecare global business unit. “The sale will generate additional resources for Solvay to invest in its strategic growth segments as part of its portfolio simplification journey.”

As part of the transaction, the business was renamed Verdant Specialty Solutions (“Verdant”), under the leadership of its new CEO, John Foley. Terms of the sale were not disclosed.